Skip to main content
. Author manuscript; available in PMC: 2012 Mar 28.
Published in final edited form as: J Cancer Ther. 2011 Jun;2(2):77–90. doi: 10.4236/jct.2011.22009

Figure 5.

Figure 5

Western blotting for biochemical feature of differentiation and determination of Bax:Bcl-2 ratio and mitochondrial Bax level in SH-SY5Y xenografts. Treatments (8 days): CTL, 4-HPR (20 μg/kg/day), GST (2 mg/kg/day), and 4-HPR (20 μg/kg/day) + 4 h later GST (2 mg/kg/day). (A) Representative Western blots (n ≥ 3) to show expression of 42 kDa β-actin, 16 kDa Id2, 21 and 24 kDa Bax, 26 kDa Bcl-2. (B) Densitometric analysis to show change in the Bax:Bcl-2 ratio. (C) Representative Western blots (n ≥ 3) to show expression of 17 kDa COX-4, 21 and 24 kDa Bax in mitochondrial fraction. (D) Densitometric analysis to show relative changes in the mitochondrial Bax level following treatments.